JP2018530557A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530557A5
JP2018530557A5 JP2018517362A JP2018517362A JP2018530557A5 JP 2018530557 A5 JP2018530557 A5 JP 2018530557A5 JP 2018517362 A JP2018517362 A JP 2018517362A JP 2018517362 A JP2018517362 A JP 2018517362A JP 2018530557 A5 JP2018530557 A5 JP 2018530557A5
Authority
JP
Japan
Prior art keywords
pyrazolo
pyridine
carboxylic acid
phenyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018517362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/056028 external-priority patent/WO2017060873A1/en
Publication of JP2018530557A publication Critical patent/JP2018530557A/ja
Publication of JP2018530557A5 publication Critical patent/JP2018530557A5/ja
Pending legal-status Critical Current

Links

JP2018517362A 2015-10-09 2016-10-07 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用 Pending JP2018530557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562239475P 2015-10-09 2015-10-09
US62/239,475 2015-10-09
PCT/IB2016/056028 WO2017060873A1 (en) 2015-10-09 2016-10-07 Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use

Publications (2)

Publication Number Publication Date
JP2018530557A JP2018530557A (ja) 2018-10-18
JP2018530557A5 true JP2018530557A5 (enExample) 2019-11-14

Family

ID=57200057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517362A Pending JP2018530557A (ja) 2015-10-09 2016-10-07 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用

Country Status (10)

Country Link
US (1) US9796711B2 (enExample)
EP (1) EP3359539A1 (enExample)
JP (1) JP2018530557A (enExample)
CN (1) CN108431002A (enExample)
AU (1) AU2016333855A1 (enExample)
BR (1) BR112018007145A2 (enExample)
CA (1) CA3001094A1 (enExample)
MX (1) MX2018004364A (enExample)
TW (1) TW201735769A (enExample)
WO (1) WO2017060873A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US11266640B2 (en) * 2017-09-20 2022-03-08 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors
GB201905711D0 (en) 2019-04-24 2019-06-05 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TW202115014A (zh) 2019-07-12 2021-04-16 美商奧佛麥德公司 用於治療囊腫纖維化之化合物
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
JP2025505230A (ja) * 2022-02-08 2025-02-21 上海奕拓醫藥科技有限責任公司 二環式ヘテロアリール化合物およびその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008147952A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
JP5637859B2 (ja) 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
PT2358680E (pt) 2008-10-23 2013-05-14 Vertex Pharma Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
DK2624695T3 (en) 2010-10-08 2016-01-04 Nivalis Therapeutics Inc NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
AU2013348018A1 (en) 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
EP2994463B1 (en) 2013-05-07 2017-10-25 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
HUE040366T2 (hu) 2013-08-08 2019-03-28 Galapagos Nv CFTR modulátor tieno[2,3-c]piránok
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
MX366556B (es) 2014-10-31 2019-07-12 Abbvie Sarl Cromanos sustituidos y metodo de uso.
JP6615213B2 (ja) 2014-10-31 2019-12-04 アッヴィ・エス・ア・エール・エル 置換テトラヒドロピランおよび使用方法

Similar Documents

Publication Publication Date Title
JP2018530557A5 (enExample)
US10988478B1 (en) Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
HRP20210935T1 (hr) Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
JP2018529743A5 (enExample)
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
RU2018115722A (ru) N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
JP2017505327A5 (enExample)
RU2484091C2 (ru) Производные изоксазоло-пиридина
JP2013526536A5 (enExample)
JP2015524798A5 (enExample)
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
AR119209A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
JP2018500376A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
RU2018105684A (ru) Замещенные трициклические соединения и способ применения
RU2020129785A (ru) Фармацевтические производные 6,5-гетеробициклического кольца
JP2015522002A5 (enExample)
HRP20190763T1 (hr) Spojevi pirazina za liječenje zaraznih bolesti
JP2015537010A5 (enExample)
HRP20210285T1 (hr) Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka
JP2024515545A5 (enExample)
US11840528B2 (en) Isoxazolyl ether derivatives as GABAA α5 PAM
JP2018522929A5 (enExample)
JP2022508523A5 (enExample)
WO2024038090A1 (en) Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance